Anti-CTFG RNAi therapy

N/A

Report date: 2022/02/08 11:21:08
NME

Base Information

Drug NameAnti-CTFG RNAi therapy
Drug Alias NameAnti-VEGF sd-rxRNA
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionProgrammed death-ligand 1 blockersRNA interference
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsHead and Neck NeoplasmsOvarian NeoplasmsMelanoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRxi Pharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesRxi Pharmaceuticals Corp
Inactive CompaniesN/A
Active IndicationsHead and Neck NeoplasmsOvarian NeoplasmsMelanoma
Inactive IndicationsCytomegalovirus Retinitis

Other Information

ATC CodeN/A
Related LinksN/A